Unregistered products
We are committed to supporting healthcare providers and patients by ensuring timely access to essential medicines, especially when registered options are unavailable or in short supply. We navigate complex regulatory pathways to deliver compliant access to unapproved or internationally registered therapeutic goods.
Special Access Scheme (SAS)
We simplify and support access to unapproved medicines under the Therapeutic Goods Administration (TGA)-governed SAS, designed for situations where:
• No registered treatment is available in Australia
• A critical illness requires urgent access to overseas therapies
• The patient is ineligible or unable to access a clinical trial
We facilitate the process to ensure that both clinicians and patients receive the necessary treatment without unnecessary delays.
Special Access Scheme (SAS)
We simplify and support access to unapproved medicines under the Therapeutic Goods Administration (TGA)-governed SAS, designed for situations where:
• No registered treatment is available in Australia
• A critical illness requires urgent access to overseas therapies
• The patient is ineligible or unable to access a clinical trial
We facilitate the process to ensure that both clinicians and patients receive the necessary treatment without unnecessary delays.
Section 19A (Medicine Shortages)
Through Section 19A approvals, we address temporary medicine shortages by sourcing overseas-registered alternatives that meet TGA standards for safety, quality, and efficacy. These alternatives ensure that patients continue to receive uninterrupted care, and clinicians can prescribe with confidence when local supply is compromised.
Authorised Prescriber Scheme (AP)
We assist prescribers in accessing unapproved medicines under the Authorised Prescriber Scheme, which allows medical practitioners to prescribe specific unapproved medicines to defined patient groups without requiring individual applications for each use.
Clinical Trials
AlgoraeRx supports clinical research by facilitating access to therapeutic goods required under the Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes, enabling sponsors and investigators to focus on trial execution with regulatory confidence.
Medicine Shortage Response
Our mission is to mitigate the effects of medicine shortages on both patients and the healthcare system. By leveraging global networks and regulatory know-how, we provide safe, effective, and timely alternatives, ensuring patients have access to their required medications when they need them most.
Registered products
We are a dedicated team of industry professionals committed to delivering high-quality, TGA and Medsafe NZ-registered pharmaceutical products to the Australian and New Zealand markets. Our focus is on ensuring patients and healthcare providers have reliable access to clinically validated, commercially available medicines.
With exclusive distribution rights for a growing portfolio of registered medicines, AlgoraeRx is equipped to manage the complex regulatory and logistical requirements of pharmaceutical distribution across Australia and New Zealand.
TGA-licensed products
For more information or specific product enquiries, please contact us directly.